{"id":38122,"date":"2023-05-01T09:56:20","date_gmt":"2023-05-01T07:56:20","guid":{"rendered":"https:\/\/kapitalpartner.dk\/?p=38122"},"modified":"2023-05-01T09:56:22","modified_gmt":"2023-05-01T07:56:22","slug":"danish-biotech-weekly-week-18","status":"publish","type":"post","link":"https:\/\/kapitalpartner.dk\/en\/danish-biotech-weekly-week-18\/","title":{"rendered":"Danish Biotech Weekly – Week 18"},"content":{"rendered":"\n

Danish Biotech Weekly with insights to listed Danish biotech companies. We keep you updated on their news flow including updates on clinical trials, acquisitions, insider trading, price targets, right issues, etc. <\/em><\/p>\n\n\n\n

In the past week, CS Medica gave an update on their joint venture with RongShi, the CEO of 2CureX bought shares, and SynAct Pharma completed recruitment for its phase 2b study.<\/strong><\/strong> 11 of the 20 listed, Danish biotech companies have published news the past week. 7 of the companies had a positive development in their share price for the week and 7 companies have had a positive share price performance year to date. Fluoguide tops chart of best performing stick this year. <\/strong><\/p>\n\n\n\n

\n
Register for the Danish Biotech Weekly newsletter<\/strong><\/a><\/div>\n<\/div>\n\n\n\n

<\/p>\n\n\n\n

Company news the past week<\/strong><\/p>\n\n\n\n

Ascendis Pharma<\/strong><\/p>\n\n\n\n

Ascendis Pharma Reports First Quarter 2023 Financial Results<\/em> (LINK)<\/a><\/p>\n\n\n\n

Biosergen<\/strong><\/a><\/p>\n\n\n\n

No news the past week<\/em><\/p>\n\n\n\n

Cessatech<\/strong><\/p>\n\n\n\n

No news the past week<\/em><\/em><\/p>\n\n\n\n

CS Medica<\/strong><\/a><\/p>\n\n\n\n

CS MEDICA Joint Venture, RongShi MEDICA (Ordos) Co. Ltd., update<\/em><\/em> (LINK)<\/a><\/p>\n\n\n\n

Curasight<\/strong><\/a><\/p>\n\n\n\n

No news the past week<\/em><\/em><\/p>\n\n\n\n

Evaxion Biotech<\/strong><\/p>\n\n\n\n

Fourth quarter and full year 2022 financial results and business update (LINK)<\/a><\/p>\n\n\n\n

Expres2ion<\/strong><\/p>\n\n\n\n

No news the past week<\/em><\/em><\/p>\n\n\n\n

Fluoguide<\/strong><\/p>\n\n\n\n

No news the past week<\/em><\/p>\n\n\n\n

Genmab<\/strong><\/p>\n\n\n\n

Genmab To File Appeal in Its Second Arbitration Under License Agreement with Janssen<\/em> (LINK)<\/a><\/p>\n\n\n\n

Gubra<\/strong><\/p>\n\n\n\n

Gubra announces the end of the stabilisation period<\/em> (LINK)<\/a><\/p>\n\n\n\n

Partial exercise of the overallotment option in connection with the initial public offering of Gubra increasing total offering size to 4,913,521 shares (LINK)<\/a><\/p>\n\n\n\n

Initiator Pharma<\/strong><\/p>\n\n\n\n

No news the past week<\/em><\/p>\n\n\n\n

IO Biotech<\/strong><\/p>\n\n\n\n

No news the past week<\/em><\/p>\n\n\n\n

Pila Pharma<\/strong><\/p>\n\n\n\n

Pila Pharma AB publishes annual report for 2022 (LINK)<\/a><\/p>\n\n\n\n

Pila Pharma AB publishes interim report (1 January \u2013 31 March 2023) (LINK)<\/a><\/p>\n\n\n\n

Saniona<\/strong><\/p>\n\n\n\n

Saniona publishes its Annual Report for 2022<\/em> (LINK)<\/a><\/p>\n\n\n\n

Scandion Oncology<\/strong><\/p>\n\n\n\n

No news past week<\/em><\/p>\n\n\n\n

SynAct Pharma<\/strong><\/p>\n\n\n\n

SynAct Pharma completes patient recruitment for Phase 2b EXPAND study of AP1189 in early severe Rheumatoid Arthritis (LINK)<\/a><\/p>\n\n\n\n

ViroGates<\/strong><\/p>\n\n\n\n

No news past week<\/em><\/p>\n\n\n\n

Zealand Pharma<\/strong><\/p>\n\n\n\n

Transactions in Zealand Pharma shares and\/or related securities by persons discharging managerial responsibilities and\/or their closely associated persons (LINK)<\/a><\/p>\n\n\n\n

Y-mAbs Therapeutics<\/strong><\/p>\n\n\n\n

Y-mAbs to Announce First Quarter 2023 Financial and Operating Results on May 8, 2023<\/em> (LINK)<\/a><\/p>\n\n\n\n

2cureX<\/strong><\/p>\n\n\n\n

2cureX\u2019s CEO Fernando Andreu purchases shares in the company (LINK)<\/a><\/p>\n\n\n\n

SELECTED CASES<\/strong><\/p>\n\n\n\n

\n
\n

Biosergen<\/a><\/strong><\/h2>\n\n\n\n
\n\n\n\n
\"\"<\/a><\/figure>\n\n\n\n
\n
Investment case<\/a><\/div>\n<\/div>\n<\/div>\n\n\n\n
\n

Curasight<\/a><\/strong><\/h2>\n\n\n\n
\n\n\n\n
\"\"<\/a><\/figure>\n\n\n\n
\n
Investment Case<\/a><\/div>\n<\/div>\n<\/div>\n\n\n\n
\n

CS Medica<\/a><\/strong><\/h2>\n\n\n\n
\n\n\n\n
\"\"<\/a><\/figure>\n\n\n\n
\n
Investment case<\/a><\/div>\n<\/div>\n<\/div>\n<\/div>\n\n\n\n

<\/p>\n\n\n\n

SHARE PRICE DEVELOPMENTS<\/strong><\/p>\n\n\n\n

There were mixed developments among the Danish Biotech stocks last week. The average return was -1,4%. 2CureX AB<\/strong> rose the most with 11% after their CEO bought shares. SynAct Pharma AB <\/strong>also performed nicely after they completed the recruitment for their Phase 2b EXPAND study of AP1189 in early severe Rheumatoid Arthritis. On the other hand, Biosergen AB <\/strong>and Evaxion Biotech A\/S <\/strong>became the worst performing Danish biotech stocks last week. Since the start of the year, most of the companies have delivered a negative return. However, the average return year-to-date is positive at 2,1% because a few companies as especially Fluoguide AB<\/strong> and Saniona AB<\/strong> have done really well.<\/p>\n\n\n\n

Read more about Fluoguide:<\/strong><\/mark> The unique cancer treatment of the future – Today’s investment<\/a><\/p>\n\n\n\n

\"\"<\/figure>\n","protected":false},"excerpt":{"rendered":"

Danish Biotech Weekly with insights to listed Danish biotech companies. We keep you updated on their news flow including updates on clinical trials, acquisitions, insider trading, price targets, right issues, etc. In the past week, CS Medica gave an update on their joint venture with RongShi, the CEO of 2CureX bought shares, and SynAct Pharma […]<\/p>\n","protected":false},"author":11,"featured_media":37397,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"mc4wp_mailchimp_campaign":[],"footnotes":""},"categories":[29,165,163,113],"tags":[],"class_list":["post-38122","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-investeringscases","category-investment-cases","category-sector-cases","category-sektorcases"],"acf":[],"yoast_head":"\nDanish Biotech Weekly - Week 18 | Kapital Partner A\/S<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/kapitalpartner.dk\/en\/danish-biotech-weekly-week-18\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Danish Biotech Weekly - Week 18 | Kapital Partner A\/S\" \/>\n<meta property=\"og:description\" content=\"Danish Biotech Weekly with insights to listed Danish biotech companies. We keep you updated on their news flow including updates on clinical trials, acquisitions, insider trading, price targets, right issues, etc. In the past week, CS Medica gave an update on their joint venture with RongShi, the CEO of 2CureX bought shares, and SynAct Pharma […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/kapitalpartner.dk\/en\/danish-biotech-weekly-week-18\/\" \/>\n<meta property=\"og:site_name\" content=\"Kapital Partner A\/S\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/kapitalpartner\" \/>\n<meta property=\"article:published_time\" content=\"2023-05-01T07:56:20+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-05-01T07:56:22+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2023\/03\/Danish-Biotech-Weekly.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1015\" \/>\n\t<meta property=\"og:image:height\" content=\"533\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Anders S\u00f8ndergaard\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@KapitalPartner\" \/>\n<meta name=\"twitter:site\" content=\"@KapitalPartner\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Anders S\u00f8ndergaard\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/kapitalpartner.dk\/en\/danish-biotech-weekly-week-18\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/kapitalpartner.dk\/en\/danish-biotech-weekly-week-18\/\"},\"author\":{\"name\":\"Anders S\u00f8ndergaard\",\"@id\":\"https:\/\/kapitalpartner.dk\/#\/schema\/person\/3225264862e39be271a9aff1c94009ed\"},\"headline\":\"Danish Biotech Weekly – Week 18\",\"datePublished\":\"2023-05-01T07:56:20+00:00\",\"dateModified\":\"2023-05-01T07:56:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/kapitalpartner.dk\/en\/danish-biotech-weekly-week-18\/\"},\"wordCount\":500,\"publisher\":{\"@id\":\"https:\/\/kapitalpartner.dk\/#organization\"},\"image\":{\"@id\":\"https:\/\/kapitalpartner.dk\/en\/danish-biotech-weekly-week-18\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2023\/03\/Danish-Biotech-Weekly.png\",\"articleSection\":[\"Investeringscases\",\"Investment cases\",\"Sector cases\",\"Sektorcases\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/kapitalpartner.dk\/en\/danish-biotech-weekly-week-18\/\",\"url\":\"https:\/\/kapitalpartner.dk\/en\/danish-biotech-weekly-week-18\/\",\"name\":\"Danish Biotech Weekly - Week 18 | Kapital Partner A\/S\",\"isPartOf\":{\"@id\":\"https:\/\/kapitalpartner.dk\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/kapitalpartner.dk\/en\/danish-biotech-weekly-week-18\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/kapitalpartner.dk\/en\/danish-biotech-weekly-week-18\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2023\/03\/Danish-Biotech-Weekly.png\",\"datePublished\":\"2023-05-01T07:56:20+00:00\",\"dateModified\":\"2023-05-01T07:56:22+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/kapitalpartner.dk\/en\/danish-biotech-weekly-week-18\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/kapitalpartner.dk\/en\/danish-biotech-weekly-week-18\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/kapitalpartner.dk\/en\/danish-biotech-weekly-week-18\/#primaryimage\",\"url\":\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2023\/03\/Danish-Biotech-Weekly.png\",\"contentUrl\":\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2023\/03\/Danish-Biotech-Weekly.png\",\"width\":1015,\"height\":533},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/kapitalpartner.dk\/en\/danish-biotech-weekly-week-18\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/kapitalpartner.dk\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Investment cases\",\"item\":\"https:\/\/kapitalpartner.dk\/en\/category\/investment-cases\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Danish Biotech Weekly – Week 18\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/kapitalpartner.dk\/#website\",\"url\":\"https:\/\/kapitalpartner.dk\/\",\"name\":\"Kapital Partner A\/S\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/kapitalpartner.dk\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/kapitalpartner.dk\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/kapitalpartner.dk\/#organization\",\"name\":\"Kapital Partner A\/S\",\"url\":\"https:\/\/kapitalpartner.dk\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/kapitalpartner.dk\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2021\/10\/Vandret-logo-PNG.png\",\"contentUrl\":\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2021\/10\/Vandret-logo-PNG.png\",\"width\":496,\"height\":432,\"caption\":\"Kapital Partner A\/S\"},\"image\":{\"@id\":\"https:\/\/kapitalpartner.dk\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/kapitalpartner\",\"https:\/\/x.com\/KapitalPartner\",\"https:\/\/www.linkedin.com\/company\/10438322\",\"https:\/\/www.youtube.com\/channel\/UCODuY5PE_fxmp2nSSsq3l3w\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/kapitalpartner.dk\/#\/schema\/person\/3225264862e39be271a9aff1c94009ed\",\"name\":\"Anders S\u00f8ndergaard\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/kapitalpartner.dk\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/27b1d0514d528cdb7505c72f554afadc?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/27b1d0514d528cdb7505c72f554afadc?s=96&d=mm&r=g\",\"caption\":\"Anders S\u00f8ndergaard\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Danish Biotech Weekly - Week 18 | Kapital Partner A\/S","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/kapitalpartner.dk\/en\/danish-biotech-weekly-week-18\/","og_locale":"en_US","og_type":"article","og_title":"Danish Biotech Weekly - Week 18 | Kapital Partner A\/S","og_description":"Danish Biotech Weekly with insights to listed Danish biotech companies. We keep you updated on their news flow including updates on clinical trials, acquisitions, insider trading, price targets, right issues, etc. In the past week, CS Medica gave an update on their joint venture with RongShi, the CEO of 2CureX bought shares, and SynAct Pharma […]","og_url":"https:\/\/kapitalpartner.dk\/en\/danish-biotech-weekly-week-18\/","og_site_name":"Kapital Partner A\/S","article_publisher":"https:\/\/www.facebook.com\/kapitalpartner","article_published_time":"2023-05-01T07:56:20+00:00","article_modified_time":"2023-05-01T07:56:22+00:00","og_image":[{"width":1015,"height":533,"url":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2023\/03\/Danish-Biotech-Weekly.png","type":"image\/png"}],"author":"Anders S\u00f8ndergaard","twitter_card":"summary_large_image","twitter_creator":"@KapitalPartner","twitter_site":"@KapitalPartner","twitter_misc":{"Written by":"Anders S\u00f8ndergaard","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/kapitalpartner.dk\/en\/danish-biotech-weekly-week-18\/#article","isPartOf":{"@id":"https:\/\/kapitalpartner.dk\/en\/danish-biotech-weekly-week-18\/"},"author":{"name":"Anders S\u00f8ndergaard","@id":"https:\/\/kapitalpartner.dk\/#\/schema\/person\/3225264862e39be271a9aff1c94009ed"},"headline":"Danish Biotech Weekly – Week 18","datePublished":"2023-05-01T07:56:20+00:00","dateModified":"2023-05-01T07:56:22+00:00","mainEntityOfPage":{"@id":"https:\/\/kapitalpartner.dk\/en\/danish-biotech-weekly-week-18\/"},"wordCount":500,"publisher":{"@id":"https:\/\/kapitalpartner.dk\/#organization"},"image":{"@id":"https:\/\/kapitalpartner.dk\/en\/danish-biotech-weekly-week-18\/#primaryimage"},"thumbnailUrl":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2023\/03\/Danish-Biotech-Weekly.png","articleSection":["Investeringscases","Investment cases","Sector cases","Sektorcases"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/kapitalpartner.dk\/en\/danish-biotech-weekly-week-18\/","url":"https:\/\/kapitalpartner.dk\/en\/danish-biotech-weekly-week-18\/","name":"Danish Biotech Weekly - Week 18 | Kapital Partner A\/S","isPartOf":{"@id":"https:\/\/kapitalpartner.dk\/#website"},"primaryImageOfPage":{"@id":"https:\/\/kapitalpartner.dk\/en\/danish-biotech-weekly-week-18\/#primaryimage"},"image":{"@id":"https:\/\/kapitalpartner.dk\/en\/danish-biotech-weekly-week-18\/#primaryimage"},"thumbnailUrl":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2023\/03\/Danish-Biotech-Weekly.png","datePublished":"2023-05-01T07:56:20+00:00","dateModified":"2023-05-01T07:56:22+00:00","breadcrumb":{"@id":"https:\/\/kapitalpartner.dk\/en\/danish-biotech-weekly-week-18\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/kapitalpartner.dk\/en\/danish-biotech-weekly-week-18\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/kapitalpartner.dk\/en\/danish-biotech-weekly-week-18\/#primaryimage","url":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2023\/03\/Danish-Biotech-Weekly.png","contentUrl":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2023\/03\/Danish-Biotech-Weekly.png","width":1015,"height":533},{"@type":"BreadcrumbList","@id":"https:\/\/kapitalpartner.dk\/en\/danish-biotech-weekly-week-18\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/kapitalpartner.dk\/en\/"},{"@type":"ListItem","position":2,"name":"Investment cases","item":"https:\/\/kapitalpartner.dk\/en\/category\/investment-cases\/"},{"@type":"ListItem","position":3,"name":"Danish Biotech Weekly – Week 18"}]},{"@type":"WebSite","@id":"https:\/\/kapitalpartner.dk\/#website","url":"https:\/\/kapitalpartner.dk\/","name":"Kapital Partner A\/S","description":"","publisher":{"@id":"https:\/\/kapitalpartner.dk\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/kapitalpartner.dk\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/kapitalpartner.dk\/#organization","name":"Kapital Partner A\/S","url":"https:\/\/kapitalpartner.dk\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/kapitalpartner.dk\/#\/schema\/logo\/image\/","url":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2021\/10\/Vandret-logo-PNG.png","contentUrl":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2021\/10\/Vandret-logo-PNG.png","width":496,"height":432,"caption":"Kapital Partner A\/S"},"image":{"@id":"https:\/\/kapitalpartner.dk\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/kapitalpartner","https:\/\/x.com\/KapitalPartner","https:\/\/www.linkedin.com\/company\/10438322","https:\/\/www.youtube.com\/channel\/UCODuY5PE_fxmp2nSSsq3l3w"]},{"@type":"Person","@id":"https:\/\/kapitalpartner.dk\/#\/schema\/person\/3225264862e39be271a9aff1c94009ed","name":"Anders S\u00f8ndergaard","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/kapitalpartner.dk\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/27b1d0514d528cdb7505c72f554afadc?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/27b1d0514d528cdb7505c72f554afadc?s=96&d=mm&r=g","caption":"Anders S\u00f8ndergaard"}}]}},"_links":{"self":[{"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/posts\/38122"}],"collection":[{"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/users\/11"}],"replies":[{"embeddable":true,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/comments?post=38122"}],"version-history":[{"count":1,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/posts\/38122\/revisions"}],"predecessor-version":[{"id":38123,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/posts\/38122\/revisions\/38123"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/media\/37397"}],"wp:attachment":[{"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/media?parent=38122"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/categories?post=38122"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/tags?post=38122"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}